Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma

An immunohistochemical study and analysis of prognostic value

Junna Oba, Takeshi Nakahara, Takeru Abe, Akihito Hagihara, Yoichi Moroi, Masutaka Furue

    Research output: Contribution to journalArticle

    24 Citations (Scopus)

    Abstract

    Background: The mitogen-activated protein kinase (MAPK) signaling pathway is one of the major cascades that are crucial for the initiation and progression of melanoma; however, the influence of these signaling molecules on patient survival has not been clarified. Objective: The purpose of this study was to analyze the protein expression of MAPK signaling molecules in melanoma, and to correlate the expression status with clinicopathologic parameters. Methods: Expression of c-Kit, phosphorylated ERK (p-ERK), and cyclin D1 was examined by immunohistochemistry in 78 primary melanomas, 24 metastatic lesions, and in 42 benign nevi. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark's level, ulceration, and survival period. Statistical analyses were performed for assessment of associations and melanoma-specific survival. Results: The expression of c-Kit, p-ERK, and cyclin D1 was significantly higher in primary melanomas than in nevi. c-Kit immunoreactivity was highest in thin (Tis-pT2) melanomas, and showed a significant reduction with tumor progression and metastasis. The expression of p-ERK was high in all stages of melanoma. Cyclin D1 positivity increased significantly according to tumor progression, but decreased in metastases. A significant correlation between p-ERK and cyclin D1 expression was observed. Survival analysis failed to detect any trends towards shorter or longer survival among patients expressing either c-Kit, p-ERK or cyclin D1. Conclusions: The expression of c-Kit, p-ERK, and cyclin D1 might help to differentiate thin melanoma from melanocytic nevus, but it appears to lack prognostic potential.

    Original languageEnglish
    Pages (from-to)116-123
    Number of pages8
    JournalJournal of Dermatological Science
    Volume62
    Issue number2
    DOIs
    Publication statusPublished - 2011 May

    Fingerprint

    Cyclin D1
    Melanoma
    Tumors
    Mitogen-Activated Protein Kinases
    Survival
    Molecules
    Nevi and Melanomas
    Neoplasm Metastasis
    Pigmented Nevus
    Neoplasms
    Nevus
    Survival Analysis
    Immunohistochemistry
    Proteins

    Keywords

    • C-Kit
    • Cyclin D1
    • Malignant melanoma
    • Mitogen-activated protein kinase
    • P-ERK
    • Survival

    ASJC Scopus subject areas

    • Dermatology
    • Biochemistry
    • Molecular Biology

    Cite this

    Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma : An immunohistochemical study and analysis of prognostic value. / Oba, Junna; Nakahara, Takeshi; Abe, Takeru; Hagihara, Akihito; Moroi, Yoichi; Furue, Masutaka.

    In: Journal of Dermatological Science, Vol. 62, No. 2, 05.2011, p. 116-123.

    Research output: Contribution to journalArticle

    Oba, Junna ; Nakahara, Takeshi ; Abe, Takeru ; Hagihara, Akihito ; Moroi, Yoichi ; Furue, Masutaka. / Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma : An immunohistochemical study and analysis of prognostic value. In: Journal of Dermatological Science. 2011 ; Vol. 62, No. 2. pp. 116-123.
    @article{9da693e6d10c4e11a6119abfd5c21a3e,
    title = "Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: An immunohistochemical study and analysis of prognostic value",
    abstract = "Background: The mitogen-activated protein kinase (MAPK) signaling pathway is one of the major cascades that are crucial for the initiation and progression of melanoma; however, the influence of these signaling molecules on patient survival has not been clarified. Objective: The purpose of this study was to analyze the protein expression of MAPK signaling molecules in melanoma, and to correlate the expression status with clinicopathologic parameters. Methods: Expression of c-Kit, phosphorylated ERK (p-ERK), and cyclin D1 was examined by immunohistochemistry in 78 primary melanomas, 24 metastatic lesions, and in 42 benign nevi. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark's level, ulceration, and survival period. Statistical analyses were performed for assessment of associations and melanoma-specific survival. Results: The expression of c-Kit, p-ERK, and cyclin D1 was significantly higher in primary melanomas than in nevi. c-Kit immunoreactivity was highest in thin (Tis-pT2) melanomas, and showed a significant reduction with tumor progression and metastasis. The expression of p-ERK was high in all stages of melanoma. Cyclin D1 positivity increased significantly according to tumor progression, but decreased in metastases. A significant correlation between p-ERK and cyclin D1 expression was observed. Survival analysis failed to detect any trends towards shorter or longer survival among patients expressing either c-Kit, p-ERK or cyclin D1. Conclusions: The expression of c-Kit, p-ERK, and cyclin D1 might help to differentiate thin melanoma from melanocytic nevus, but it appears to lack prognostic potential.",
    keywords = "C-Kit, Cyclin D1, Malignant melanoma, Mitogen-activated protein kinase, P-ERK, Survival",
    author = "Junna Oba and Takeshi Nakahara and Takeru Abe and Akihito Hagihara and Yoichi Moroi and Masutaka Furue",
    year = "2011",
    month = "5",
    doi = "10.1016/j.jdermsci.2011.02.011",
    language = "English",
    volume = "62",
    pages = "116--123",
    journal = "Journal of Dermatological Science",
    issn = "0923-1811",
    publisher = "Elsevier Ireland Ltd",
    number = "2",

    }

    TY - JOUR

    T1 - Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma

    T2 - An immunohistochemical study and analysis of prognostic value

    AU - Oba, Junna

    AU - Nakahara, Takeshi

    AU - Abe, Takeru

    AU - Hagihara, Akihito

    AU - Moroi, Yoichi

    AU - Furue, Masutaka

    PY - 2011/5

    Y1 - 2011/5

    N2 - Background: The mitogen-activated protein kinase (MAPK) signaling pathway is one of the major cascades that are crucial for the initiation and progression of melanoma; however, the influence of these signaling molecules on patient survival has not been clarified. Objective: The purpose of this study was to analyze the protein expression of MAPK signaling molecules in melanoma, and to correlate the expression status with clinicopathologic parameters. Methods: Expression of c-Kit, phosphorylated ERK (p-ERK), and cyclin D1 was examined by immunohistochemistry in 78 primary melanomas, 24 metastatic lesions, and in 42 benign nevi. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark's level, ulceration, and survival period. Statistical analyses were performed for assessment of associations and melanoma-specific survival. Results: The expression of c-Kit, p-ERK, and cyclin D1 was significantly higher in primary melanomas than in nevi. c-Kit immunoreactivity was highest in thin (Tis-pT2) melanomas, and showed a significant reduction with tumor progression and metastasis. The expression of p-ERK was high in all stages of melanoma. Cyclin D1 positivity increased significantly according to tumor progression, but decreased in metastases. A significant correlation between p-ERK and cyclin D1 expression was observed. Survival analysis failed to detect any trends towards shorter or longer survival among patients expressing either c-Kit, p-ERK or cyclin D1. Conclusions: The expression of c-Kit, p-ERK, and cyclin D1 might help to differentiate thin melanoma from melanocytic nevus, but it appears to lack prognostic potential.

    AB - Background: The mitogen-activated protein kinase (MAPK) signaling pathway is one of the major cascades that are crucial for the initiation and progression of melanoma; however, the influence of these signaling molecules on patient survival has not been clarified. Objective: The purpose of this study was to analyze the protein expression of MAPK signaling molecules in melanoma, and to correlate the expression status with clinicopathologic parameters. Methods: Expression of c-Kit, phosphorylated ERK (p-ERK), and cyclin D1 was examined by immunohistochemistry in 78 primary melanomas, 24 metastatic lesions, and in 42 benign nevi. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark's level, ulceration, and survival period. Statistical analyses were performed for assessment of associations and melanoma-specific survival. Results: The expression of c-Kit, p-ERK, and cyclin D1 was significantly higher in primary melanomas than in nevi. c-Kit immunoreactivity was highest in thin (Tis-pT2) melanomas, and showed a significant reduction with tumor progression and metastasis. The expression of p-ERK was high in all stages of melanoma. Cyclin D1 positivity increased significantly according to tumor progression, but decreased in metastases. A significant correlation between p-ERK and cyclin D1 expression was observed. Survival analysis failed to detect any trends towards shorter or longer survival among patients expressing either c-Kit, p-ERK or cyclin D1. Conclusions: The expression of c-Kit, p-ERK, and cyclin D1 might help to differentiate thin melanoma from melanocytic nevus, but it appears to lack prognostic potential.

    KW - C-Kit

    KW - Cyclin D1

    KW - Malignant melanoma

    KW - Mitogen-activated protein kinase

    KW - P-ERK

    KW - Survival

    UR - http://www.scopus.com/inward/record.url?scp=79954579925&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79954579925&partnerID=8YFLogxK

    U2 - 10.1016/j.jdermsci.2011.02.011

    DO - 10.1016/j.jdermsci.2011.02.011

    M3 - Article

    VL - 62

    SP - 116

    EP - 123

    JO - Journal of Dermatological Science

    JF - Journal of Dermatological Science

    SN - 0923-1811

    IS - 2

    ER -